Cytosorbents (CTSO) Assets (2010 - 2026)

Cytosorbents (CTSO) has 17 years of Assets data on file, last reported at $40.6 million in Q1 2026.

• For the quarter ending Q1 2026, Assets fell 20.12% year-over-year to $40.6 million; the trailing twelve-month figure through Mar 2026 stood at $40.6 million (down 20.12% YoY), and the FY2025 full-year result was $44.2 million, down 6.73% from the prior year.
• Assets for Q1 2026 stood at $40.6 million, down from $44.2 million in the prior quarter.
• Across five years, Assets topped out at $83.3 million in Q1 2022 and bottomed at $40.6 million in Q1 2026.
• The 5-year median for Assets is $50.8 million (2025), against an average of $53.8 million.
• The widest annual swing landed in 2022, when Assets plunged 34.5%; it then gained 7.88% in 2025.
• A 5-year view of Assets shows it stood at $63.2 million in 2022, then dropped by 16.25% to $53.0 million in 2023, then declined by 10.55% to $47.4 million in 2024, then retreated by 6.73% to $44.2 million in 2025, then slipped by 8.19% to $40.6 million in 2026.
• The last three Assets figures came in at $40.6 million (Q1 2026), $44.2 million (Q4 2025), and $45.8 million (Q3 2025), per Business Quant data.

Peer Comparison